Luspatercept (MDS-LR with RS or post-ESA failure)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-LUSPATERCEPT |
|---|
| ID | REG-LUSPATERCEPT-MDS-LR |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-COMMANDS-FENAUX-2020 SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 |
Notes
Originally established as 2L (MEDALIST: RS-MDS post-ESA failure). COMMANDS later established luspatercept as 1L over ESA for transfusion-dependent LR-MDS broadly. SF3B1+ / RS subtype shows strongest benefit. NOT registered in Ukraine — pragmatic 1L in our setting remains ESA. STUB — requires clinical co-lead signoff before publication.
Used By
Indication
IND-MDS-LR-1L-LUSPATERCEPT- IND-MDS-LR-1L-LUSPATERCEPT